Leaflet XAMIOL 50mcg/0.5mg / g gel


Indicated for: psoriasis

Route of administration: cutaneous

Substance: calcipotriol + betamethasone (immunomodulator + glucocorticoid)

ATC: D05AX52 (Dermatologicals | Antipsoriatics for topical use | Other antipsoriatics for topical use)

Calcipotriol and betamethasone are used together for the treatment of plaque psoriasis, a chronic skin condition characterized by red patches covered with whitish scales. This combination reduces inflammation, itching, and slows down the excessive growth of skin cells.

Calcipotriol is a vitamin D analog that helps normalize the cell regeneration process, while betamethasone is a potent corticosteroid that reduces inflammation and suppresses local immune reactions.

The treatment is applied topically, usually in the form of an ointment or gel, and is intended for short-term use to avoid corticosteroid-related side effects. It is important to avoid application on the face, skin folds, or areas with thin skin.

Side effects may include local irritation, burning sensation, or itching. Long-term use can lead to skin thinning or other corticosteroid-related complications.

General data about XAMIOL 50mcg/0.5mg / g

  • Substance: calcipotriol + betamethasone
  • Date of last drug list: 01-07-2015
  • Commercial code: W54663001
  • Concentration: 0.5mg / g
  • Pharmaceutical form: gel
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for calcipotriol + betamethasone

Concentrations available for calcipotriol + betamethasone

  • 0.5mg/g
  • 50mcg/0.5mg/g